Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2015 May 31;42(4):375–389. doi: 10.1007/s10928-015-9419-z

Fig. 2.

Fig. 2

PK/PD model simulation of the experimental rifampin dose-fractionation study for TB infected BALB/c mice described in Jayaram et al. [12]. Individual data points (⋄) were PK/PD model generated, with each point obtained from the simulation of total lung CFU’s and corresponding PK/PD index calculated from simulated plasma concentrations for each dosage regimen of the dose-fractionation study. Solid lines are Emax equation fits (Table 2) to the PK/PD model generated data points.